Dronedarone for the treatment of atrial fibrillation with concomitant heart failure and preserved or mildly reduced ejection fraction: closer to Ithaca after a long odyssey?

Eur J Heart Fail. 2022 Jun;24(6):1102-1105. doi: 10.1002/ejhf.2519. Epub 2022 May 11.

Authors

Giuseppe Boriani¹, Jacopo Francesco Imberti^{1

2

3}, Marco Vitolo^{1

2

3}

Affiliations

¹ Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
² Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
³ Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK.

PMID: 35481867
DOI: 10.1002/ejhf.2519

No abstract available

Publication types

Editorial
Comment

MeSH terms

Atrial Fibrillation* / complications
Atrial Fibrillation* / drug therapy
Dronedarone / therapeutic use
Heart Failure* / complications
Heart Failure* / drug therapy
Humans
Stroke Volume

Substances

Dronedarone